Protecting blood stem cells from DNA damage
Protection of hematopoietic stem progenitor cells from endogenous DNA damage
This study is looking for ways to protect important blood-making cells from damage caused by harmful substances, specifically for people with Fanconi anemia, to help prevent serious issues like bone marrow failure and cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11062869 on NIH RePORTER |
What this research studies
This research investigates how to protect hematopoietic stem cells (HSCs), which are crucial for producing blood cells, from DNA damage caused by reactive aldehydes. The study will utilize advanced techniques like CRISPR technology to identify and enhance the enzymes that detoxify these harmful substances. By using a model that mimics human conditions, the researchers aim to discover new ways to prevent DNA damage in patients with Fanconi anemia, a condition that makes them particularly vulnerable. The ultimate goal is to develop therapies that can prevent bone marrow failure and related cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Fanconi anemia or those at risk of bone marrow failure due to DNA damage.
Not a fit: Patients without any genetic predisposition to bone marrow failure or those not affected by DNA damage-related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect patients with Fanconi anemia from severe blood-related complications.
How similar studies have performed: Previous research has shown promise in using CRISPR technology for gene editing and enhancing cellular functions, indicating potential success for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Jung, Moonjung — Johns Hopkins University
- Study coordinator: Jung, Moonjung
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.